Subsequently, we used blebbistatin, a specific inhibitor of MYH9, to treat lung cancer in vivo, and found that after treatment with blebbistatin, the growth of LCCs was inhibited in a dose-dependent manner. The gene discussed is MYH9; the disease is lung carcinoma.